Cambium Bio (ASX:CMB) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CMB Cambium Bio Ltd ASX:CMB
25 GF Score
Price A$0.50
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ASX:CMB
25GF Score
Cambium Bio Ltd ASX:CMB
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio Business Description

Address 31 Lexington Drive, Unit 2.06, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is an Australian clinical-stage regenerative medicine company developing biologic therapies for ophthalmology and tissue repair. Its core technology platform is based on human platelet lysate, which it uses to build a pipeline of novel therapeutics. The lead product candidate, Elate Ocular, is being developed to address unmet medical needs in dry eye disease. The company also applies a stem cell platform, Progenza, to therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio operates primarily in the United States, where its development activities and target markets are concentrated. As a clinical-stage company, it does not yet generate product revenue; its business depends on research and development progress, regulatory milestones, and financing from investors or partners rather than commercial sales.
25GF Score

Get the complete analysis for ASX:CMB

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.50
Price